香港股市 已收市

  • 恒指

    18,057.45
    +402.04 (+2.28%)
     

  • 國指

    6,262.61
    +163.35 (+2.68%)
     

  • 上證綜指

    3,132.43
    +47.73 (+1.55%)
     

  • 滬深300

    3,738.93
    +66.49 (+1.81%)
     

  • 美元

    7.8197
    -0.0003 (-0.00%)
     

  • 人民幣

    0.9327
    -0.0011 (-0.12%)
     

  • 道指

    33,963.84
    -106.58 (-0.31%)
     

  • 標普 500

    4,320.06
    -9.94 (-0.23%)
     

  • 納指

    13,211.81
    -12.18 (-0.09%)
     

  • 日圓

    0.0525
    -0.0003 (-0.55%)
     

  • 歐元

    8.3300
    -0.0044 (-0.05%)
     

  • 英鎊

    9.5700
    -0.0410 (-0.43%)
     

  • 紐約期油

    90.33
    +0.70 (+0.78%)
     

  • 金價

    1,944.90
    +5.30 (+0.27%)
     

  • Bitcoin

    26,555.00
    -83.12 (-0.31%)
     

  • CMC Crypto 200

    565.87
    -2.18 (-0.38%)
     

Why Merck Stock Is Trading Higher Today

Vandana Singh
·1 分鐘文章

Merck & Co Inc's (NYSE: MRK) Q1 sales reached $14.49 billion, down 9% Y/Y, beating the consensus of $13.79 billion.

Excluding Lagevrio (COVID-19 treatment), sales growth was 11%; excluding Lagevrio and the impact of foreign exchange, growth was 15%.

Pharmaceutical sales decreased by 10% to $12.72 billion, primarily due to lower sales in virology, mainly attributable to Lagevrio, and diabetes, partially offset by growth in oncology, vaccines, and hospital acute care.

Lagevrio Q1 sales declined 88% Y/Y to $392 million. Ketruda sales grew 20% to $5.8 billion. Gardasil/Gardasil 9 sales grew 35% to $2.0 billion.

Adjusted EPS of $1.40 also surpassed the analysts' estimate of $1.32 and declined 35% Y/Y.

View more earnings on MRK

Also Read: Merck Acquires Prometheus Biosciences For $10.8B, Strengthening Its Immunology Pipeline.

Moderna Inc (NASDAQ: MRNA) and Merck's cancer vaccine exhibited positive results against relapse for melanoma patients.

About 79% of high-risk melanoma patients who got the personalized vaccine and Merck's immunotherapy Keytruda were alive and cancer-free at 18 months, compared with about 62% of patients who received immunotherapy alone.

2023 Guidance: Merck has raised and narrowed FY23 adjusted EPS guidance to $6.88-$7.00 compared to prior guidance of $6.80-$6.95 and consensus of $6.91.

Merck anticipates FY23 sales Of $57.7-$58.9 billion compared to previously expected $57.2-$58.7 billion and the consensus of $58.28 billion.

Price Action: MRK shares are up 2.29% at $116.03 during the premarket session on the last check Thursday.

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Why Merck Stock Is Trading Higher Today originally appeared on Benzinga.com

.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.